Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension

NCT03088254 is registered in ClinicalTrials.gov with Jeil Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03088254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension
Lead sponsor
Jeil Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2016
Completion date
December 4, 2017
Enrollment
126 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia with hypertension